header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

TRANEXAMIC ACID REDUCES TRANSFUSION RATES IN OBESE AND SUPER OBESE PATIENTS UNDERGOING TOTAL JOINT ARTHROPLASTY

International Society for Technology in Arthroplasty (ISTA) 31st Annual Congress, London, England, October 2018. Part 1.



Abstract

Background

While tranexamic acid (TXA) has been well shown to reduce blood loss after joint replacement surgery, little is known regarding its effectiveness in obese patients. The aim of this study was to evaluate the effect of TXA changes in hematocrit and hemoglobin levels as well as incidence of packed red blood cell (pRBC) transfusions in obese patients undergoing total joint arthroplasty (TJA).

Material and Methods

Between January 2014 and May 2015, 420 consecutive primary joint replacements were performed by two surgeons at our institution. 157 patients (THA=29; TKA=128) were obese with a body mass index (BMI) greater than or equal to 30 kg/m2. Medical records were reviewed and identified that TXA was utilized in 85 (54.1%) arthroplasties [study group] and was compared to a consecutive series of 72 (45.9%) TJAs [control group]. TXA was given intravenously(IV) in two doses: (1) one gram prior to incision and (2) one gram at the time of femoral preparation in THA or prior to cementation in TKA. Changes in hemoglobin and hematocrit levels, number of pRBC transfusions, and occurrence of thrombolytic events were recorded.

Results

The changes in hematocrit (7.2% vs. 8.1%) and hemoglobin levels (3.0 g/dl vs. 3.3 g/dl) were less for group that received TXA than the control group, albeit not significantly (p=0.100 and p=0.278, respectively). Within the control group 26 (36.1%) patients required a pRBC transfusion with a mean of 2.0 units per patient (range:1–5); whereas, only 8 (9.4%) patients with TXA required a mean of 1.6 units per patient (range:1–2 units). The use of TXA significantly reduced the incidence of pRBC transfusions, especially in TKA (p<0.001). Sub-analyses revealed that transfusion rates were even more significantly reduced by TXA in obesity type II and III. Two pulmonary emboli were reported in the group that did not receive TXA, whereas no thrombolytic events were reported in the group that did receive TXA.

Conclusion

Utilization of TXA significantly reduced the rate of pRBC transfusions in obese patients.


Email: